Bioxyne Limited

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:46 2024-04-30 am EDT 5-day change 1st Jan Change
0.006 AUD -25.00% Intraday chart for Bioxyne Limited -33.33% -45.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bioxyne to Raise AU$1.45 Million via Share Issuance MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50% MT
Bioxyne Limited Announces Retirement of N H Chua as Director CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11% MT
Bioxyne Limited Extends Amazon Footprint into US and Japan CI
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings MT
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8% MT
Bioxyne Limited Appoints Jason Hine as Director CI
Bioxyne Acquires Breathe Life Sciences MT
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd. CI
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4% MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Bioxyne's Fiscal H1 Revenue Declines MT
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4% MT
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million. CI
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer CI
Bioxyne Sells 49% Stake in Direct Selling Business MT
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million. CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Bioxyne Limited Announces Board Changes CI
Bioxyne Posts Higher Sales Revenue in First Nine-Months of FY22 MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Bioxyne's Revenue Surges 12% in Half-Year Ended Dec. 31, 2021 MT
Chart Bioxyne Limited
More charts
Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.
More about the company
  1. Stock Market
  2. Equities
  3. BXN Stock
  4. News Bioxyne Limited
  5. Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%